The global pharmaceutical contract sales organizations market size is expected to reach USD 16.3 billion by 2030, registering a CAGR of 8.4% from 2023 to 2030. High adoption of new technologies for contract sales by pharmaceutical contract sales organizations (CSO), an increase in the interest among end-users to increase the sales of biopharmaceutical and small molecule drugs, and the surge in demand for reducing the cost associated with in-house sales are some of the key factors supporting the growth of the industry. Over the years, the number of new drug launches has increased.
For instance, according to the IQVIA report on R&D trends, 84 new active substances were launched globally in 2021, which was double as compared to the last five years. The increase in drug launches globally is expected to improve the demand for contract sales services, which is likely to support industry growth. Prescription drug sales are witnessing a steady rise. For instance, according to Evaluate Pharma, worldwide total prescription drug sales accounted for USD 1,066 billion in 2021 and will reach USD 1,612 billion by 2028. The growing demand for sales among pharmaceutical companies is expected to improve the demand for CSO services for pharmaceuticals in the post-pandemic period.
For instance, according to the IQVIA report on R&D trends, 84 new active substances were launched globally in 2021, which was double as compared to the last five years. The increase in drug launches globally is expected to improve the demand for contract sales services, which is likely to support industry growth. Prescription drug sales are witnessing a steady rise. For instance, according to Evaluate Pharma, worldwide total prescription drug sales accounted for USD 1,066 billion in 2021 and will reach USD 1,612 billion by 2028. The growing demand for sales among pharmaceutical companies is expected to improve the demand for CSO services for pharmaceuticals in the post-pandemic period.
Pharmaceutical Contract Sales Organizations Market Report Highlights
- Based on service, the personal promotion segment dominated the industry in 2022. A rise in the R&D activities of pharmaceutical companies is expected to increase the number of new drug launches, and approvals are expected to support the segment growth
- The pharmaceutical companies end-use segment held the largest revenue share in 2022 due to the high competition among pharmaceutical companies in product sales, promoting the demand for an efficient team to support their sales activities
- North America held the largest revenue share in 2022. A significant number of drugs were launched in the region in the previous years, especially in the U.S., which is one of the key factors supporting the region’s growth
- Moreover, the region’s public organization is steadily focused on supporting R&D activities by providing funding. This has further supported the region’s growth
Table of Contents
Chapter 1. Methodology and Scope1.1. Market Segmentation & Scope
1.1.1. Service
1.1.2. End-use
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Volume price analysis (Model 2)
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
1.9.3. Objective 3
1.9.4. Objective 4
Chapter 2. Executive Summary
2.1. Market Outlook
Chapter 3. Pharmaceutical Contract Sales Organization Market (CSO) Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increase the R&D activities on drugs and increase in the drug pipeline
3.2.1.2. Growing interest of pharmaceutical companies to increase the sales of the products
3.2.1.3. Adoption of digital technologies by Pharmaceutical Contract Sales Organizations
3.2.2. Market restraint analysis
3.2.2.1. Quality issues associated with outsourcing
3.2.3. Covid-19 Impact & Recovery Analysis
3.2.4. Industry Analysis - Porter’s Five Forces
3.2.5. PESTLE Analysis
Chapter 4. Pharmaceutical Contract Sales Organization Market (CSO): Service Segment Analysis
4.1. Pharmaceutical Contract Sales Organization Market (CSO) Market: Definition & Scope
4.2. Pharmaceutical Contract Sales Organization Market (CSO) Market: Service Market Share Analysis, 2022 & 2030
4.2.1. Personal Promotion
4.2.1.1. Personal promotion market, 2018 - 2030 (USD Million)
4.2.1.2. Promotional sales team
4.2.1.2.1. Promotional sales team market, 2018 - 2030 (USD Million)
4.2.1.3. Key account management
4.2.1.3.1. Key account management market, 2018 - 2030 (USD Million)
4.2.1.4. Vacancy Management
4.2.1.4.1. Vacancy Management market, 2018 - 2030 (USD Million)
4.2.2. Non-Personal Promotion
4.2.2.1. Non-Personal promotion market, 2018 - 2030 (USD Million)
4.2.2.2. Medical affairs solutions
4.2.2.2.1. Medical affairs solutions market, 2018 - 2030 (USD Million)
4.2.2.3. Remote medical science liaisons
4.2.2.3.1. Remote medical science liaisons market, 2018 - 2030 (USD Million)
4.2.2.4. Nurse (clinical) educators
4.2.2.4.1. Nurse (clinical) educators market, 2018 - 2030 (USD Million)
4.2.2.5. Others
4.2.2.5.1. Others market, 2018 - 2030 (USD Million)
Chapter 5. Pharmaceutical Contract Sales Organization Market (CSO): End-use Segment Analysis
5.1. Pharmaceutical Contract Sales Organization Market (CSO) Market: Definition & Scope
5.2. Pharmaceutical Contract Sales Organization Market (CSO) Market: End Use Market Share Analysis, 2022 & 2030
5.2.1. Pharmaceutical Companies
5.2.1.1. Pharmaceutical companies Market, 2018 - 2030 (USD Million)
5.2.2. Biopharmaceutical Companies
5.2.2.1. Biopharmaceutical companies Market, 2018 - 2030 (USD Million)
Chapter 6. Pharmaceutical Contract Sales Organization Market (CSO): Regional Analysis
6.1. Pharmaceutical Contract Sales Organization Market (CSO): Regional market share analysis, 2022 & 2030
6.2. North America
6.2.1. North America Market estimates and forecast, 2018 - 2030
6.2.2. U.S.
6.2.2.1. U.S. Market estimates and forecast, 2018 - 2030
6.2.3. Canada
6.2.3.1. Canada Market estimates and forecast, 2018 - 2030
6.3. Europe
6.3.1. Europe Market estimates and forecast, 2018 - 2030
6.3.2. U.K.
6.3.2.1. U.K. Market estimates and forecast, 2018 - 2030
6.3.3. Germany
6.3.3.1. Germany Market estimates and forecast, 2018 - 2030
6.3.4. France
6.3.4.1. France Market estimates and forecast, 2018 - 2030
6.3.5. Italy
6.3.5.1. Italy Market estimates and forecast, 2018 - 2030
6.3.6. Spain
6.3.6.1. Spain Market estimates and forecast, 2018 - 2030
6.3.7. Denmark
6.3.7.1. Denmark Market estimates and forecast, 2018 - 2030
6.3.8. Sweden
6.3.8.1. Sweden Market estimates and forecast, 2018 - 2030
6.3.9. Norway
6.3.9.1. Norway Market estimates and forecast, 2018 - 2030
6.4. Asia Pacific
6.4.1. Asia Pacific Market estimates and forecast, 2018 - 2030
6.4.2. Japan
6.4.2.1. Japan Market estimates and forecast, 2018 - 2030
6.4.3. China
6.4.3.1. China Market estimates and forecast, 2018 - 2030
6.4.4. India
6.4.4.1. India Market estimates and forecast, 2018 - 2030
6.4.5. South Korea
6.4.5.1. South Korea Market estimates and forecast, 2018 - 2030
6.4.6. Australia
6.4.6.1. Australia Market estimates and forecast, 2018 - 2030
6.4.7. Thailand
6.4.7.1. Thailand Market estimates and forecast, 2018 - 2030
6.5. Latin America
6.5.1. Latin America Market estimates and forecast, 2018 - 2030
6.5.2. Brazil
6.5.2.1. Brazil Market estimates and forecast, 2018 - 2030
6.5.3. Mexico
6.5.3.1. Mexico Market estimates and forecast, 2018 - 2030
6.5.4. Argentina
6.5.4.1. Argentina Market estimates and forecast, 2018 - 2030
6.6.MEA
6.6.1. MEA Market estimates and forecast, 2018 - 2030
6.6.2. South Africa
6.6.2.1. South Africa Market estimates and forecast, 2018 - 2030
6.6.3. Saudi Arabia
6.6.3.1. Saudi Arabia Market estimates and forecast, 2018 - 2030
6.6.4. UAE
6.6.4.1. UAE Market estimates and forecast, 2018 - 2030
6.6.5. Kuwait
6.6.5.1. Kuwait Market estimates and forecast, 2018 - 2030
Chapter 7. Competitive Landscape
7.1. CMIC HOLDINGS Co., LTD
7.1.1.1. Company overview
7.1.1.2. Financial performance
7.1.1.3. Service benchmarking
7.1.1.4. Strategic initiatives
7.2. Axxelus
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Service benchmarking
7.2.1.4. Strategic initiatives
7.3. EPS Corporation.
7.3.1.1. Company overview
7.3.1.2. Financial performance
7.3.1.3. Service benchmarking
7.3.1.4. Strategic initiatives
7.4. QFR SOLUTIONS
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Service benchmarking
7.4.1.4. Strategic initiatives
7.5. MaBico
7.5.1.1. Company overview
7.5.1.2. Financial performance
7.5.1.3. Service benchmarking
7.5.1.4. Strategic initiatives
7.6. Mednext Pharma Private Limited
7.6.1.1. Company overview
7.6.1.2. Financial performance
7.6.1.3. Service benchmarking
7.6.1.4. Strategic initiatives
7.7. Peak Pharma Solutions Inc.
7.7.1.1. Company overview
7.7.1.2. Financial performance
7.7.1.3. Service benchmarking
7.7.1.4. Strategic initiatives
7.8. IQVIA, Inc.
7.8.1.1. Company overview
7.8.1.2. Financial performance
7.8.1.3. Service benchmarking
7.8.1.4. Strategic initiatives
7.9. Promoveo Health
7.9.1.1. Company overview
7.9.1.2. Financial performance
7.9.1.3. Service benchmarking
7.9.1.4. Strategic initiatives
7.10. Syneous Health
7.10.1.1. Company overview
7.10.1.2. Financial performance
7.10.1.3. Service benchmarking
7.10.1.4. Strategic initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of Abbreviations
List of Figures
Fig. 1 Market research process
Fig. 2 Information Procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market segmentation & scope
Fig. 8 Pharmaceutical CSO market outlook, 2018 - 2030
Fig. 9 Market trends & outlook
Fig. 10 Market driver relevance analysis (Current & future impact)
Fig. 11 Market restraint relevance analysis (Current & future impact)
Fig. 12 SWOT Analysis, By Factor (political & legal, economic and technological)
Fig. 13 Porter’s Five Forces Analysis
Fig. 14 Pharmaceutical CSO market: Service outlook key takeaways
Fig. 15 Pharmaceutical CSO market: Service movement analysis
Fig. 16 Personal Promotion market, 2018 - 2030 (USD Million)
Fig. 17 Promotional sales team market, 2018 - 2030 (USD Million)
Fig. 18 Key account management market, 2018 - 2030 (USD Million)
Fig. 19 Vacancy management market, 2018 - 2030 (USD Million)
Fig. 20 Non-personal Promotion market, 2018 - 2030 (USD Million)
Fig. 21 Medical affairs solutions market, 2018 - 2030 (USD Million)
Fig. 22 Remote medical science liaisons market, 2018 - 2030 (USD Million)
Fig. 23 Nurse (clinical) educators market, 2018 - 2030 (USD Million)
Fig. 24 Others market, 2018 - 2030 (USD Million)
Fig. 25 Pharmaceutical CSO market: End-use outlook key takeaways
Fig. 26 Pharmaceutical CSO market: End-use movement analysis
Fig. 27 Pharmaceutical companies market, 2018 - 2030 (USD Million)
Fig. 28 Biopharmaceutical companies market, 2018 - 2030 (USD Million)
Fig. 29 Regional marketplace: Key takeaway
Fig. 30 Pharmaceutical CSO market regional outlook, 2020 & 2028
Fig. 31 North America Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 32 U.S. Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 33 Canada Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 34 Europe Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 35 Germany Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 36 France Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 37 U.K. Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 38 Spain Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 39 Italy Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 40 Denmark Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 41 Sweden Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 42 Norway Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 43 Asia Pacific Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 44 Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 45 Japan Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 46 India Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 47 Thailand Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 48 South Korea Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 49 Australia Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 50 Latin America Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 51 Brazil Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 52 Mexico Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 53 Argentina Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 54 Middle East & Africa Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 55 South Africa Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 56 Saudi Arabia Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 57 UAE Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Fig. 58 Kuwait Pharmaceutical CSO market, 2018 - 2030 (USD Million)
Companies Mentioned
- CMIC HOLDINGS Co., LTD
- Axxelus
- EPS Corporation.
- QFR SOLUTIONS
- MaBico
- Mednext Pharma Private Limited
- Peak Pharma Solutions Inc.
- IQVIA, Inc.
- Promoveo Health
- Syneous Health
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | February 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 8.6 Billion |
| Forecasted Market Value ( USD | $ 16.3 Billion |
| Compound Annual Growth Rate | 8.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
